Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?

Cancer Radiother. 2022 Oct;26(6-7):858-864. doi: 10.1016/j.canrad.2022.06.020. Epub 2022 Aug 17.


Despite recent advances, the prognosis of pancreatic adenocarcinomas remains poor, even for patients with resectable tumors. For these latter, new approaches based on neoadjuvant treatment have been developed. Two components are used: chemotherapy and radiation therapy (RT). Indeed, pre-operative RT has many advantages in terms of efficacy and tolerance. It increases notably the chances of subsequent complete tumor resection. Several prospective trials are currently ongoing to clarify its place in the therapeutic arsenal. Another crucial question is to know which is the best RT technique: conventional normofractionated chemoradiotherapy or hypofrationated stereotactic body RT?

Keywords: Adenocarcinoma; Adénocarcinome; Cancer du pancréas; Chemoradiation; Chimioradiothérapie; FOLFIRINOX; Neoadjuvant treatment; Pancreatic cancer; Radiothérapie stéréotaxique; Stereotactic body radiation therapy; Traitement néoadjuvant.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Adenocarcinoma* / radiotherapy
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemoradiotherapy
  • Humans
  • Neoadjuvant Therapy
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / radiotherapy
  • Prospective Studies